Klaricid Iv

Clarithromycin, the active ingredient in Klaricid Iv, is a macrolide antibiotic presented as an intravenous solution for intravenous use. It is indicated for the treatment of bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, skin and soft tissue infections, bronchitis, and otitis media in adult patients. It is manufactured under EU GMP standards.

GNH USA supplies Klaricid Iv as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution across EU and other markets, ensuring quality and regulatory compliance.

Clarithromycin is a macrolide antibiotic used to treat bacterial infections of the respiratory and skin pathways. - Community‑acquired pneumonia: Reduces bacterial load and improves clinical outcomes in adult patients. - Acute bacterial sinusitis: Clears infection and relieves sinus inflammation. - Skin and soft tissue infections: Controls bacterial growth and promotes healing of cellulitis and abscesses. - Bronchitis: Alleviates bacterial bronchial infection and improves cough symptoms. - Otitis media: Eradicates middle‑ear pathogens and restores hearing function.

Clarithromycin may cause adverse reactions ranging from mild to serious.

Common Side Effects: - Nausea: Mild stomach upset occurring shortly after infusion. - Diarrhea: Loose stools that may be self‑limiting. - Taste disturbance: Altered or metallic taste during treatment.

Serious or Rare Side Effects: - Hepatotoxicity: Elevated liver enzymes or jaundice requiring monitoring. - QT prolongation: Potential cardiac rhythm disturbances in susceptible patients. - Severe allergic reactions: Anaphylaxis or skin rash demanding immediate medical attention.

Clarithromycin requires careful consideration of patient‑specific factors before use. - Renal impairment: Adjust therapy based on clinical response and monitor renal function. - Hepatic dysfunction: Monitor liver enzymes regularly during treatment. - QT prolongation risk: Avoid in patients with known cardiac arrhythmias or electrolyte disturbances. - Drug interactions: Review concomitant medications for CYP3A4 inhibitors and adjust as needed. - Pregnancy and lactation: Use only if benefits outweigh potential risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Clarithromycin interacts with several drugs that may alter its safety or efficacy.

Major Interactions (Avoid): - Erythromycin, ketoconazole, ritonavir: May increase clarithromycin levels leading to toxicity. - Cisapride, pimozide: Heightened risk of severe QT prolongation. - Statins metabolized by CYP3A4 (e.g., simvastatin): Increased risk of myopathy.

Moderate Interactions (Monitor Closely): - Warfarin: May enhance anticoagulant effect; monitor INR closely. - Theophylline: May raise serum concentrations; monitor for toxicity.